Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials

OBJECTIVES: Combination treatment with erlotinib plus bevacizumab has the potential to become a standard treatment regimen for patients with epidermal growth factor receptor mutation-positive (EGFRm(+)) advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Wusheng, Wang, Ke, Jiang, Yun, Li, Dingbin, Bao, Chongxi, Luo, Jing, Liu, Liuyuan, Huang, Bing, Kong, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396158/
https://www.ncbi.nlm.nih.gov/pubmed/35985780
http://dx.doi.org/10.1136/bmjopen-2022-062036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396158/
https://www.ncbi.nlm.nih.gov/pubmed/35985780
http://dx.doi.org/10.1136/bmjopen-2022-062036

Ejemplares similares